TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8676625

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m2 per day on days 1-5 for six courses)
Number of subjects: 196

Group type: COMPARATOR
Intervention: CAP (cyclophosphamide 750 mg/m2 per day and doxorubicin 50 mg/m2 per day on day 1, and prednisone 40 mg/m2 per day on days 1-5 for six courses)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fludarabine in pretreated cases
Number of subjects: 196

Group type: COMPARATOR
Intervention: CAP in pretreated cases
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fludarabine in untreated cases
Number of subjects: 196

Group type: COMPARATOR
Intervention: CAP in untreated cases
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fludarabine and CAP (side effects)
Number of subjects: 196
Study: 1736033

Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (50% carbohydrate calories, 30% fat calories, 20% protein calories)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fat-based diet (28% carbohydrate calories, 55% fat calories, 17% protein calories)
Number of subjects: 12
Study: 6093845

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Higher dose of ketoconazole
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30449625

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab
Number of subjects: 987

Group type: COMPARATOR
Intervention: Radiotherapy plus cisplatin
Number of subjects: 987
Study: 28265973

Group type: COMPARATOR
Intervention: Weight gain in overweight and obese women
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Weight loss in overweight and obese women
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Stable weight in overweight and obese women
Number of subjects: 1173
Study: 25289840

Group type: EXPERIMENTAL
Intervention: Low-load resistance training with concurrent blood flow restriction (BFR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-load resistance training alone (control)
Number of subjects: 40
Study: 23945213

Group type: EXPERIMENTAL
Intervention: CMI-168
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22016276

Group type: EXPERIMENTAL
Intervention: Isotretinoin 1 mg/kg/day (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isotretinoin 1 mg/kg alternate day (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isotretinoin 1 mg/kg/day for one week/four weeks (Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isotretinoin 20 mg every alternate day for 16 weeks (Group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 19076262

Group type: EXPERIMENTAL
Intervention: COPEing with Toddler Behaviour parent training program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 79
Study: 16883263

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, followed by 75 mg/day after Day 2) in addition to conventional therapy (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional therapy only (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Number of subjects: 107
Study: 15151582

Group type: EXPERIMENTAL
Intervention: Individualized course of dexamethasone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard 42-day course of dexamethasone
Number of subjects: 33
Study: 11216738

Group type: EXPERIMENTAL
Intervention: Aprotinin 0.5 million KIU before incision and 0.5 million KIU during initiation of cardiopulmonary bypass
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 9928580

Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years) plus Goserelin (2 years)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Tamoxifen (3 years)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Alternating adjuvant chemotherapy
Number of subjects: 662

Group type: COMPARATOR
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 662
Study: 8035946

Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/d) for 1 week
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 3270665

Group type: EXPERIMENTAL
Intervention: PT-01 (controlled release strips containing ofloxacin) applied site (T)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo-applied site (P)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control site (C)
Number of subjects: 27
Study: 1232533

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) plus a 4‐week course of cyclophosphamide (DES + CTX)
Number of subjects: 50
Study: 30488800

Group type: EXPERIMENTAL
Intervention: Deprox 500® (2 tablets/day for 6 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Serenoa repens (320 mg, 1 tablet/day for 6 weeks)
Number of subjects: 63
Study: 28723906

Group type: EXPERIMENTAL
Intervention: GBLUP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBayesB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBayesA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBayesCπ
Number of subjects: 0
Study: 25434394

Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro bioassay using sera from matched patients
Number of subjects: 0
Study: 23531379

Group type: EXPERIMENTAL
Intervention: Bolus fluid resuscitation
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Control arm (standard of care without bolus fluid)
Number of subjects: 3600
Study: 21921100

Group type: EXPERIMENTAL
Intervention: Strategy 1 (referral if at least 1 of the following criteria is present: inflammatory back pain, HLA‐B27, or sacroiliitis detected by imaging)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Strategy 2 (referral if 2 out of 5 criteria are positive: inflammatory back pain, HLA‐B27, sacroiliitis detected by imaging, positive family history of ankylosing spondylitis, or good treatment response to NSAIDs)
Number of subjects: 560
Study: 19734968

Group type: EXPERIMENTAL
Intervention: Surgery (preferred treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various treatment modalities (not specified)
Number of subjects: 0
Study: 16846517

Group type: EXPERIMENTAL
Intervention: Diabetes Manual intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Deferred intervention (control)
Number of subjects: 250
Study: 15315512

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Pregabalin (effective dose range 150-600 mg/day)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Pregabalin (two times daily vs three times daily)
Number of subjects: 1052
Study: 11143188

Group type: EXPERIMENTAL
Intervention: 7-day intravenous eflornithine (100 mg/kg every 6 h)
Number of subjects: 321

Group type: COMPARATOR
Intervention: 14-day regimen of eflornithine
Number of subjects: 321
Study: 9269608

Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Influenza vaccine and bacterial immunostimulant
Number of subjects: 66
Study: 8371842

Group type: EXPERIMENTAL
Intervention: Cold pressor test (I test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold pressor test with contralateral non-noxious stimulus (II test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold pressor test with contralateral noxious stimulus (III test)
Number of subjects: 0
Study: 3690187

Group type: EXPERIMENTAL
Intervention: BCG Glaxo (Evans Medical Ltd, Dunstable, UK)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BCG Pasteur (L'Institut Pasteur, France)
Number of subjects: 21
Study: 31997715

Group type: EXPERIMENTAL
Intervention: ZILVER PTX stent
Number of subjects: 220

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 220
Study: 29695250

Group type: EXPERIMENTAL
Intervention: Girls Active programme
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 1752
Study: 26879049

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (n = 34)
Number of subjects: 69
Study: 24096751

Group type: EXPERIMENTAL
Intervention: Checklist during simulated trauma resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No checklist during simulated trauma resuscitation
Number of subjects: 0
Study: 22094636

Group type: EXPERIMENTAL
Intervention: TetraMen-T (alternative formulations)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Neisvac-C (licensed adjuvanted serogroup C conjugate vaccine)
Number of subjects: 378
Study: 20797475

Group type: EXPERIMENTAL
Intervention: Flaxseed lignan (SDG) 100 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flaxseed lignan (SDG) 20 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18996857

Group type: EXPERIMENTAL
Intervention: MUFA diet (35-45% of energy, >20% as monounsaturated fatty acids; n = 54)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: LF diet (20-30% of energy; n = 51)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control diet (35% of energy as fat; n = 26)
Number of subjects: 131
Study: 16640064

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Tinnitus Masking (TM)
Number of subjects: 118
Study: 12755526

Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion at 4 mcg/mL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion at 5 mcg/mL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion at 6 mcg/mL
Number of subjects: 69
Study: 11184063

Group type: EXPERIMENTAL
Intervention: Dietary therapy candidates according to NCEP II guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Dietary therapy candidates according to European guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy candidates according to NCEP II guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy candidates according to European guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Dietary therapy received by diagnosed dietary therapy candidates according to NCEP II guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Dietary therapy received by diagnosed dietary therapy candidates according to European guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy received by diagnosed drug therapy candidates according to NCEP II guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Antilipemic drug therapy received by diagnosed drug therapy candidates according to European guidelines
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Diagnosis of high blood cholesterol levels among NCEP II drug therapy candidates
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Diagnosis of high blood cholesterol levels among European drug therapy candidates
Number of subjects: 2078
Study: 8783307

Group type: EXPERIMENTAL
Intervention: Coloured Analogue Scale (CAS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 104
Study: 8270437

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus hyperthermia
Number of subjects: 41

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 41
Study: 3370412

Group type: EXPERIMENTAL
Intervention: Iothalamate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 45
Study: 31586600

Group type: EXPERIMENTAL
Intervention: SB206 4% twice daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: SB206 8% twice daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: SB206 12% twice daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: SB206 12% once daily
Number of subjects: 256

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: SB206 (all doses)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: SB206 4%, 8%, and 12% twice daily
Number of subjects: 256
Study: 30630791

Group type: EXPERIMENTAL
Intervention: Treatment group (exposed to clopidogrel and aspirin)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (not exposed to clopidogrel and aspirin)
Number of subjects: 180
Study: 26952245

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6491
Study: 26073395

Group type: COMPARATOR
Intervention: 0 g/d EPA + DHA (placebo)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.85 g/d EPA + DHA (low dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3.4 g/d EPA + DHA (high dose)
Number of subjects: 25
Study: 23750465

Group type: EXPERIMENTAL
Intervention: High treatment dose (high attendance, exposure completion)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: High patient engagement (homework adherence, commitment)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Low treatment dose (low attendance, exposure completion)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Low patient engagement (low homework adherence, commitment)
Number of subjects: 439
Study: 21445641

Group type: EXPERIMENTAL
Intervention: Intravenous selenite as a bolus-loading dose of 2,000 μg Se followed by continuous infusion of 1,600 μg Se per day for 10 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravenous selenite
Number of subjects: 35
Study: 18279770

Group type: EXPERIMENTAL
Intervention: Irbesartan (not specified dosage or duration)
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study: 17097993

Group type: EXPERIMENTAL
Intervention: Amiodarone (prescribed for at least 30 days before transplantation)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (patients not prescribed amiodarone)
Number of subjects: 396
Study: 14586350

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol 25 mug every 3 hours
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Intracervical 16F Foley catheter
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Combination misoprostol-Foley catheter
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study: 10722450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Intranasal zanamivir
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Inhaled plus intranasal zanamivir
Number of subjects: 575
Study: 7788012

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg iv 2 h before tests)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Insulin hypoglycemia
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: GHRH, Insulin, Clonidine
Number of subjects: 53
Study: 1973202

Group type: EXPERIMENTAL
Intervention: Sydnocarb
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 517586

Group type: EXPERIMENTAL
Intervention: 2,000 U heparin/12 hr subcutaneously
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5,000 U heparin/12 hr subcutaneously
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 75
Study: 31010891

Group type: EXPERIMENTAL
Intervention: Lean methods applied to CAD/CAM education
Number of subjects: 66

Group type: COMPARATOR
Intervention: Existing teaching methods (Control)
Number of subjects: 66
Study: 25890673

Group type: EXPERIMENTAL
Intervention: E/C/F/tenofovir alafenamide
Number of subjects: 1733

Group type: COMPARATOR
Intervention: E/C/F/tenofovir disoproxil fumarate
Number of subjects: 1733
Study: 23527645

Group type: EXPERIMENTAL
Intervention: Regular prospective memory tasks with less focal cues
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Irregular prospective memory tasks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Retrospective memory for irregular tasks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cues that reduce executive control demands
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Increased retrospective memory demand
Number of subjects: 52
Study: 21451098

Group type: EXPERIMENTAL
Intervention: 8-day university course for physical therapists
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 42
Study: 19859531

Group type: COMPARATOR
Intervention: sdNVP alone
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: NVP/CBV4 (sdNVP with AZT plus 3TC for 4 days)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: NVP/CBV7 (sdNVP with AZT plus 3TC for 7 days)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: NVP/CBV4 and NVP/CBV7 combined
Number of subjects: 406
Study: 16507190

Group type: EXPERIMENTAL
Intervention: 0.015 mg morphine (Group I, n=25)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.03 mg morphine (Group II, n=30)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.06 mg morphine (Group III, n=31)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.25 mg morphine (Group IV, n=33)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (Control group, n=25)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All morphine groups
Number of subjects: 144
Study: 14967752

Group type: EXPERIMENTAL
Intervention: Easy breath-hold instruction
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inhale/easy breath-hold instruction
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hard breath-hold instruction
Number of subjects: 150
Study: 11354530

Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical nephrectomy
Number of subjects: 0
Study: 9480239

Group type: EXPERIMENTAL
Intervention: Non-pregnant women with RSA
Number of subjects: 117

Group type: COMPARATOR
Intervention: Healthy non-pregnant multigravidas (control)
Number of subjects: 117
Study: 7695707

Group type: EXPERIMENTAL
Intervention: Plantar strike technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tendon strike technique
Number of subjects: 12
Study: 2902264

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) measles vaccine, 40,000 PFU at 4 months of age
Number of subjects: 239

Group type: COMPARATOR
Intervention: Schwarz measles vaccine, 6000 TCID50 at 9 months of age
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: EZ vaccine
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 239
Study: 31840247

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) of the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study: 31230384

Group type: EXPERIMENTAL
Intervention: Organ Care System (OCS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cold Storage (CS)
Number of subjects: 39
Study: 28664912

Group type: EXPERIMENTAL
Intervention: Combined biomarker panel (IGFBP2, LCAT, CA125)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CA125 alone
Number of subjects: 80
Study: 25923481

Group type: EXPERIMENTAL
Intervention: High protein diet (protein enriched bread and protein enriched drinking yoghurt; n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular diet (regular bread and regular drinking yoghurt; n=17)
Number of subjects: 34
Study: 23447519

Group type: EXPERIMENTAL
Intervention: Cholic acid (CA) 15 mg/kg per day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21374656

Group type: EXPERIMENTAL
Intervention: PEG‐IFN/ribavirin therapy
Number of subjects: 281
Study: 19919189

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM)
Number of subjects: 221
Study: 17024948

Group type: EXPERIMENTAL
Intervention: Conventional GIC (Ketac-Fil Plus Aplicap) on sound dentin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Conventional GIC (Ketac-Fil Plus Aplicap) on artificially created carious dentin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: RMGIC (Photac-Fil Aplicap) on sound dentin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: RMGIC (Photac-Fil Aplicap) on artificially created carious dentin
Number of subjects: 4
Study: 12492800

Group type: EXPERIMENTAL
Intervention: HES 450/0.7/4.6
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HES 70/0.5/4
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HES 200/0.6/9.4
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HES 130/0.4/9
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50
Study: 11103114

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of urapidil (group U, n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nothing (group N, n = 22)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of urapidil (group U)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nothing (group N)
Number of subjects: 44
Study: 9179227

Group type: EXPERIMENTAL
Intervention: 90Y/111In-DOTA-peptide-ChL6
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Therapeutic doses of 90Y-DOTA-peptide-ChL6
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Tracer doses of 111In-DOTA-peptide-ChL6
Number of subjects: 3

Group type: COMPARATOR
Intervention: 90Y-DOTA-peptide-ChL6
Number of subjects: 3
Study: 1489548

Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine, a serotonin re-uptake inhibitor
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7